TEST:

Oncotype DX Breast Recurrence Score®Test

Both MammaPrint and OncotypeDX tests improve identifying candidates for chemotherapy among women with early breast cancer, with broadly equivalent clinical usefulness. The tests should be implemented into existing risk algorithms to maximize their clinical usefulness.

Three lymph node metastases were identified. Oncotype DX was performed but was judged inconclusive due to insufficient tumor tissue.

Our data provides a snapshot of the real-world allocation of multigene testing in early breast cancer, and supports other studies in highlighting the discrepancy between IHC-based and gene-based luminal subtyping. Ki67 evaluation remained consistent over time, and the use of AI for Ki67 scoring did not enhance the accuracy of IHC-based luminal subtyping.

Findings show that EIC status is the most significant predictor of RD following BCSs with close DCIS margins. This emphasizes the importance of identifying EIC-positive cases in pathology reports and prioritizing them for additional re-excision when DCIS margins are close.

Clinical-genomic discordance was common. RS reflected tumor biology rather than nodal status, and chemotherapy use depended more on genomic-clinical concordance than CR alone. Integration of clinical and genomic risk is essential for optimizing adjuvant strategies in early HR+/HER2- breast cancer.

P2, N=1260, Recruiting, MedSIR | Active, not recruiting --> Recruiting

P=N/A, N=4000, Not yet recruiting, Gangnam Severance Hospital

Using comparable tools, such as ME2, may reduce financial toxicity in this population and overall costs to the system. Larger study recommended.

 The Magee Equation 3 (ME3) is a reliable, simple, and cost-effective tool that correlates well with the CTS5 model, making it a practical alternative for predicting recurrence risk and guiding treatment decisions in breast cancer.

The results of this study demonstrate high concordance of RS results between paired samples, which supports the use of CNB for Oncotype DX testing.

This study is the first to establish a CENP-based prognostic model for BC, offering novel biomarkers and potential therapeutic targets for personalized treatment. Additionally, the biological function of the key molecule MMP1 was validated through both in vitro and in vivo experiments.

Socioeconomic- and insurance-based inequities, including both overtreatment and undertreatment, were observed in this EHR-based cohort of women with early-stage breast cancer eligible for ODX testing, indicating opportunities to increase care quality.